What is behind programmatic treatment outcome definitions for tuberculosis?
Eur Respir J
.
2020 Jul 23;56(1):2001751.
doi: 10.1183/13993003.01751-2020.
Print 2020 Jul.
Authors
Zaza Avaliani
1
,
Ogtay Gozalov
2
,
Giorgi Kuchukhidze
2
,
Alena Skrahina
3
,
Viorel Soltan
4
,
Martin van den Boom
2
,
Irina Vasilyeva
5
,
Valentina Vilc
6
,
Askar Yedilbayev
7
Affiliations
1
National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.
2
WHO Regional Office for Europe, Copenhagen, Denmark.
3
Republican Research and Practical Center for Pulmonology and Tuberculosis, Minsk, Belarus.
4
Stop TB Partnership, Geneva, Switzerland.
5
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Moscow, Russian Federation.
6
Institute of Phthisiopneumology, Chisinau, Republic of Moldova.
7
WHO Regional Office for Europe, Copenhagen, Denmark yedilbayeva@who.int.
PMID:
32703821
DOI:
10.1183/13993003.01751-2020
No abstract available
Publication types
Editorial
MeSH terms
Antitubercular Agents / therapeutic use
Humans
Treatment Outcome
Tuberculosis* / diagnosis
Tuberculosis* / drug therapy
Tuberculosis* / epidemiology
Tuberculosis, Multidrug-Resistant* / drug therapy
Substances
Antitubercular Agents
Grants and funding
001/WHO_/World Health Organization/International